In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 111 to 120 of 391

TitleTypeExpected publication date
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age [ID6484]Highly specialised technology
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Technology appraisal guidanceTBC
Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID6235Technology appraisal guidanceTBC
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]Technology appraisal guidanceTBC
Dupilumab for treating severe chronic rhinosinusitis with nasal polyps (review of TA648) [ID6480]Technology appraisal guidance
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]Technology appraisal guidanceTBC
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]NICE guidelineTBC
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy [ID5073]Technology appraisal guidance
Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All